DOCSLIB.ORG

Business Developer Vol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Business Developer Vol Published monthly euroPLX 71 Lisbon (Portugal) November 25 + 26, 2019 by RauCon GmbH & Co. KG Rudolf-Diesel-Str. 9 69115 Heidelberg, Germany Business Developer Vol. 15 # 5 | May | 2019 Company Mergers and Acquisitions Abound: Less Management Changes * Acquisition: Aura Health Inc. has market for gene therapies. 20 May name to Zyla Life Sciences in the which Evotec will acquire Just closed the acquisition of an 80% 2019 (www.catalent.com) coming weeks. The name change Biotherapeutics, Inc., for up to $ equity interest in Pharmadrug reflects an intention to shift the 90 m including potential perfor- * Licensing and Distribution: Production GmbH for total consid- company’s focus from an abuse- mance-based earn-out compo- Cumberland Pharmaceuticals eration of €5.0 million in a move to deterrent technology company to nents expected within the next Inc. has entered into an exclu- enter the Europan market. 17 May a broader commercial life sciences three years. Just Biotherapeutics sive agreement with China’s 2019 (www.aurahealthinc.com) business committed to bringing is a unique technology company Winhealth Pharma Group for the important products to patients that integrates highly synergistic * Name change: Blake Insomnia licensing rights of Acetadote® and healthcare providers. 16 May scientific expertise and ML driven Therapeutics, Inc has submitted a (acetylcysteine) Injection, used to 2019 (www.egalet.com) technologies for design, develop- name change request to rebrand prevent or reduce liver damage ment, and manufacturing of bio- as BioHemp International. 15 May resulting from acetaminophen * Distribution: Emerald Health logics. 20 May 2019 (www.evotec. 2019 (www.biohempinternational. overdose, and Caldolor® (ibupro- Therapeutics, Inc. has been com) com/) fen) Injection, which is used to authorised by PEI Cannabis and treat pain and fever in the hospital Manitoba Liquor & Lotteries * Acquisition: Roche and Spark * Toll manufacture: Cantargia AB setting. The agreement will pro- Corporation to supply Emerald- Therapeutics, Inc. intend to refile and Patheon Biologics B.V. (part vide Winhealth licensing rights to branded cannabis products into on or about 23 May 2019 their of ThermoFischer Scientific) have commercialise both FDA approved those provinces. Emerald has also respective Premerger Notification signed an agreement regarding drugs in China. 15 May 2019 fulfilled its first shipments of pre- and Report Forms under the future production of the antibody (www.cumberlandpharma.com) mium cannabis products to PEI Hart-Scott-Rodino Act, in order CAN04 (nidanilimab). CAN04 Cannabis and to licensed private to provide the U.S. government is currently in phase IIa clinical * Acquisition: Cure Pharmaceutical, retailers in Saskatchewan. 14 May additional time to complete its development for non-small cell an innovative drug delivery and 2019 (emeraldhealth.ca/en) review of the proposed $4.8 billion lung cancer and pancreatic cancer. development company, has closed transaction. 14 May 2019 (www. 13 May 2019 (cantargia.com) on the previously announced * Acquisition: EVER Pharma roche.com) acquisition of Chemistry Holdings Holding Ges.m.b.H (Austria) * Acquisition: Catalent, Inc., has Inc., a formulation technology announced that it has com- * Acquisition: H. Lundbeck A/S completed the $1.2 billion acquisi- company that is developing inno- pleted the acquisition of Amneal and and Abide Therapeutics, Inc. tion of Paragon Bioservices, Inc., a vative delivery systems for a vari- Deutschland GmbH, a subsidiary signed a definitive agreement in leading viral vector development ety of industries. The acquisition of Amneal Pharmaceuticals that which Lundbeck LLC has agreed to and manufacturing partner for was an all-stock transaction using operates the company’s commer- acquire Abide. Under the terms of gene therapies. With the addition common stock. In connection cial operations in Germany. The the agreement, Lundbeck may pay of Paragon’s specialised expertise with the signing and closing of acquired entity will be rebranded USD 250 million (approximately in adeno-associated virus (AAV) this acquisition, CURE received a to EVER Pharma GmbH. Financial DKK 1.65 billion) upfront with a vectors, the most commonly used total of $10M in cash. 14 May 2019 terms were not disclosed. 17 May commitment to pay future devel- vector to deliver DNA to cells, (www.curepharmaceutical.com) 2019 (www.everpharma.com) opment and sales milestones to Catalent is positioned to capitalise the group of current owners of up on strong industry tailwinds in the * Name change: Egalet Corp or- * Acquisition: Evotec AG signed to USD 150 million (approximately potentially $40 billion addressable ation announced it will change its a definitive agreement under DKK 1 billion). This acquisition pro- vides Lundbeck a novel discovery of higher-risk MDS (HR-MDS). 13 to Ethicon as part of its strategy Clermont Ferrand, France, is an platform and a U.S.-based research May 2019 (www.onconova.com) to focus on core business areas. independant, family-owned phar- hub. 6 May 2019 (www.lundbeck. akeda will receive $3.4 billion maceutical company focusing on * New facility: Pfizer Inc. open a com) upfront in cash and up to an microbiome medicine: discovery, new 175,000 square-foot manu- additional $1.9 billion in poten- product development, clinical * Distribution: Lupin Limited and facturing facility in Andover, Mass. tial milestone payments from studies and manufacturing of Live Aptissen S.A. have entered into a Pfizer’s Andover site houses Novartis, and approximately Biotherapeutic Products. definitive distribution agreement commercial manufacturing and $400 million upfront in cash from under which Aptissen has granted product development functions, Based in Radomir, Danhson-BG Ethicon. 8 May 2019 (www.takeda. Lupin the exclusive rights to mar- with colleagues dedicated to (www.danhson.bg) is a Bulgarian, co.jp) ket, distribute and sell the current the development and produc- privately owned holding company Aptissen products in Canada. tion of high-quality complex that develops, manufactures and BD People on the Move This includes immediate rights to biologics and vaccines. With its markets branded generic prod- distribute Synolis VA for the treat- modular and flexible design, the * Accord Healthcare Ltd.: Cerem ucts. The company is a part of an ment of Osteoarthritis. 9 May 2019 newly opened Andover Clinical Çavdar, who has been Manager international group with business (www.lupin.com) Manufacturing Facility (ACMF) will for Business Development and operations in Bulgaria, Russia, the expand the capacity for Pfizer’s In-Licensing, EMENA, left the com- CIS countries and South-East Asia. * Spin off: Nimble Therapeutics BioTherapeutics Pharmaceutical pany. (Corp Comm 5 May 2019) has begun operating as a stan- Being part of the Group Medigray, Sciences organisation to manufac- dalone business after spinning DR Pharma is a privately owned ture clinical supplies. Pfizer’s ACMF * Biocon Ltd: Yash Khosla, until out from F. Hoffmann La Roche pharmaceutical company manu- investment is over $200 million most recently Director of Business to commercialise its proprietary facturer and marketer of gener- and includes five independent Development & Licensing at Lupin chemical synthesis technology for ics products in Central America, manufacturing suites to advance Europe Ltd. has been has been drug discovery and development. Dominican Republic, and Peru, Pfizer’s robust pipeline of potential appointed as Regional Head of 30 Apr 2019 (www.nimblethera- with offices in San José, Costa Rica. new biotherapeutics and vaccines, Europe & ANZ and is registered for peutics.com) The company is based in San José, with more than 50 projects in euroPLX 70 Berlin. (Pers Comm 14 May 2019) Costa Rica. * Acquisition: Novartis has entered development. 9 May 2019 (www. pfizer.com) into an agreement with Takeda * CytoDyn, Inc.: Brendan Rae, Excella GmbH & Co. KG is the Pharmaceutical Company Limited German manufacturing site of * Acquisition: Pfizer Inc. has Ph.D., J.D., who comes from Serina to acquire the assets associated Fareva, a Luxembourg based com- entered into a definitive agree- Therapeutics where he was Chief with Xiidra® (lifitegrast ophthalmic pany focusing on research, manu- ment to acquire all the shares of Business Officer, responsible for solution) 5% worldwide, a pre- facturing and packaging solutions Therachon Holding AG, a privately- partnering, out licensing and over- scription treatment approved to for cosmetic, make-up, pharma- held clinical-stage biotechnology all company strategy has been treat both signs and symptoms of ceutical, industrial and household company focused on rare diseases, appointed as Senior Vice President dry eye by inhibiting inflammation products. with assets in development for of Business Development. (Press caused by the disease. Deal terms Release 14 May 2019) the treatment of achondroplasia Located in Hohenlockstedt, include a USD 3.4 billion upfront and short bowel syndrome (SBS). Germany, G. Pohl-Boskamp payment with potential milestone * Phytopharm Kl ka S.A.: Paula Under the terms of the agreement, GmbH & Co. KG (www.pohl- payments of up to USD 1.9 billion. Lecka, who has been Business Pfizer will acquire Therachon boskamp.de) is one of Germany’s As part of the agreement, Novartis Development Manager finished for $340 million upfront with an leading mid-sized pharmaceutical will be taking on approximately her employment for the company. additional $470 million in addi-
Load more

Recommended publications
  • Pharma Limited. Lupin Limited, Lupin
    Case 8:15-cv-03437-GJH Document 1 Filed 11/10/15 Page 1 of 17 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND SHIRE PHARMACEUTICAL DEVELOPMENT INC., SHIRE DEVELOPMENT LLC, COSMO TECHNOLOGIES LIMITED, and NOGRA Civil Action No. PHARMA LIMITED. Plaintiffs, v. LUPIN LIMITED, LUPIN PHARMACEUTICALS INC., LUPIN INC., and LUPIN ATLANTIS HOLDINGS SA Defendants. COMPLAINT Plaintiffs Shire Pharmaceutical Development Inc., Shire Development LLC (collectively, "Shire"), Cosmo Technologies Limited ("Cosmo"), and Nogra Pharma Limited ("Nogra") (collectively, "Plaintiffs") by their undersigned attomeys, for their Complaint against defendants Lupin Limited ("Lupin Ltd."), Lupin Pharmaceuticals Inc. ("LPI"), Lupin Inc. ("Lupin Inc."), and Lupin Atlantis Holdings SA ("Lupin Atlantis") (collectively "Lupin" or "Defendants") herein, allege as follows: NATURE OF THE ACTION l. This is a civil action for patent infringement arising under the patent laws of the United States, Title 35, United States Code, involving United States Patent No.6,773,720 ("the '720 patent" or "the patent-in-suit"), attached hereto as Exhibit A. Case 8:15-cv-03437-GJH Document 1 Filed 11/10/15 Page 2 of 17 THE PARTIES 2. Plaintiff Shire Pharmaceutical Development Inc. is a corporation organized and existing under the laws of the state of Maryland, having its principal place of business at 1200 Morris Drive, Wayne, PA 19087. 3. Plaintiff Shire Development LLC is a limited liability company organized and existing under the laws of the State of Delaware, having its principal place of business at735 Chesterbrook Boulevard and 1200 Monis Drive, Wayne, Pennsylvania 19087. 4. Plaintiff Cosmo is a company organized and existing under the laws of Ireland, having its principal place of business at The Connolly Building, 42-43 Amiens Street, Dublin l, Ireland.
    [Show full text]
  • S.No. NAME of APPLICANT IEC NO. 1 IBM INDIA PRIVATE LIMITED 0797006486 2 MAGSONS EXPORTS 0588055743 3 SHAHI EXPORTS PRIVATE LIMI
    AEO T2 CERTIFIED ENTITIES S.No. NAME OF APPLICANT IEC NO. 1 IBM INDIA PRIVATE LIMITED 0797006486 2 MAGSONS EXPORTS 0588055743 3 SHAHI EXPORTS PRIVATE LIMITED 0588085481 4 NIPPON PAINT INDIA PRIVATE LIMITED 0505090619 5 DANFOSS INDIA PRIVATE LIMITED 0598045848 6 HONDA CARS INDIA LIMITED 0595049338 7 ANUPAM COLOURS PRIVATE LIMITED 0301012610 8 BOSCH AUTOMOTIVE ELECTRONICS INDIA PRIVATE LIMITED 0708022308 9 BOSCH LIMITED 0788000314 10 VELANKANI ELECTRONICS PRIVATE LIMITED 0715009729 11 FERRERO INDIA PRIVATE LIMITED 0707029953 12 SIEMENS LIMITED 0388070005 13 ENCUBE ETHICALS PRIVATE LIMITED 0396057993 14 NESTLE INDIA LIMITED 0588000531 15 3M INDIA LIMITED 0793012112 16 BIOLOGICAL E. LIMITED 0988000229 17 TOYOTA KIRLOSKAR MOTOR PRIVATE LIMITED 0797012451 18 MICROMAX INFORMATICS LIMITED 0503028665 19 3M ELECTRO & COMMUNICATION INDIA PRIVATE LIMITED 0493021329 20 DELL INTERNATIONAL SERVICES INDIA PRIVATE LIMITED 5196000691 21 EMBARKATION HEADQUARTERS 0307061281 22 USHODAYA ENTERPRISES PRIVATE LIMITED 0988001071 23 SAMSUNG INDIA ELECTRONICS PRIVATE LIMITED 0595032818 24 LENOVO INDIA PRIVATE LIMITED 0705001091 25 KUNDAN CARE PRODUCTS LIMTED 0504074008 26 INA BEARINGS INDIA PRIVATE LIMITED 3197032462 27 SCHNEIDER ELECTRIC INDIA PRIVATE LIMITED 0595007317 28 ORDNANCE FACTORY BOARD MUMBAI OFFICE MINISTRY OF DEFENCE 0307084434 29 JABIL CIRCUIT INDIA PRIVATE LIMITED 0302051139 30 KASTURI AND SONS LIMITED 0488007542 31 POPPYS KNITWEAR PRIVATE LIMITED 0488013011 32 ASTRA MICROWAVE PRODUCTS LIMITED 0991002300 33 CATERPILLAR INDIA PRIVATE LIMITED 0400023067
    [Show full text]
  • Lupin Limited: Rating Removed from Watch with Developing Implications
    November 20, 2019 Lupin Limited: Rating removed from watch with developing implications Summary of rating action Instrument* Previous Rated Amount Current Rated Amount Rating Action (Rs. crore) (Rs. crore) Short-term Fund-based 1,100.0 1,100.0 [ICRA]A1+, removed from Limits rating watch with developing implications Short-term Non-fund 400.0 400.0 [ICRA]A1+; removed from Based Limits rating watch with developing implications Total 1,500.0 1,500.0 *Instrument details are provided in Annexure-1 Material event Lupin Limited, on November 11, 2019, announced that it has approved the divestment of its entire equity interest (representing 99.82% of the issued and paid-up capital) of Kyowa Pharmaceutical Industry Co. Ltd (Kyowa) by way of sale of shares to Plutus Limited (an entity affiliated with Unison Capital partners) at an enterprise value (EV) of JPY 57,361 million (Rs.3702 crore), subject to necessary approvals including Japan Fair Trade Commission and shareholders of the company. The proposed transaction is an all cash-transaction, valued at EV/sales of 2 times and will result in post- tax net cash inflow of ~JPY 32,596 million (Rs. 2,104 crore). The transaction is expected to be concluded within FY2020. Impact of material event ICRA has a short-term rating of [ICRA]A1+ (pronounced ICRA A one plus) assigned to the Rs. 1,100-crore short-term fund- based limits and Rs. 400-crore short-term non-fund based limits. The rating has been removed from watch with developing implications. Rationale The removal of the rating watch factors in the expected strengthening of the credit profile of Lupin Limited, following the divestment of Kyowa (which accounted for 10.6% of consolidated operating income (OI) and 9.1% of OPBDITA of Lupin in FY2019), along with receipt of post-tax cash proceeds of JPY 32,596 million (Rs.2,104 crore).
    [Show full text]
  • United States Court of Appeals for the Federal Circuit ______
    Case: 16-1973 Document: 3-2 Page: 1 Filed: 07/20/2017 NOTE: This disposition is nonprecedential. United States Court of Appeals for the Federal Circuit ______________________ OTSUKA PHARMACEUTICAL CO., LTD., Plaintiff-Appellant v. ZYDUS PHARMACEUTICALS USA, INC., CADILA HEALTHCARE, LIMITED, MYLAN INC., MYLAN PHARMACEUTICALS INC., TORRENT PHARMACEUTICALS LIMITED, TORRENT PHARMA INC., HETERO LABS LIMITED, AJANTA PHARMA LIMITED, AJANTA PHARMA USA INC., AUROBINDO PHARMA LTD., INTAS PHARMACEUTICALS LIMITED, ACCORD HEALTHCARE, INC., AUROBINDO PHARMA USA INC., AUROLIFE PHARMA LLC, LUPIN LIMITED, LUPIN ATLANTIS HOLDINGS S.A., LUPIN PHARMACEUTICALS, INC., ALEMBIC PHARMACEUTICALS LIMITED, AMNEAL PHARMACEUTICALS, LLC, AMNEAL PHARMACEUTICALS INDIA PVT. LTD., Defendants-Appellees ______________________ 2016-1962, 2016-1963, 2016-1964, 2016-1966, 2016-1968, 2016-1970, 2016-1971, 2016-1972, 2016-1973, 2016-1974, 2016-1975, 2016-1978 ______________________ Appeals from the United States District Court for the District of New Jersey in Nos. 1:14-cv-03168-JBS-KMW, Case: 16-1973 Document: 3-2 Page: 2 Filed: 07/20/2017 1:14-cv-04508-JBS-KMW, 1:14-cv-04671-JBS-KMW, 1:14- cv-05876-JBS-KMW, 1:14-cv-06158-JBS-KMW, 1:14-cv- 06890-JBS-KMW, 1:14-cv-07105-JBS-KMW, 1:14-cv- 07252-JBS-KMW, 1:14-cv-07405-JBS-KMW, 1:14-cv- 08074-JBS-KMW, 1:14-cv-08077-JBS-KMW, 1:15-cv- 01585-JBS-KMW, Chief Judge Jerome B. Simandle. ______________________ JUDGMENT ______________________ PAUL WILLIAM BROWNING, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Washington, DC, argued for plaintiff-appellant. Also represented by JAMES B. MONROE, CHARLES THOMAS COLLINS-CHASE, ERIC JAY FUES, ANDREA DENISE MAIN; JEFFREY ANDREW FREEMAN, Atlanta, GA.
    [Show full text]
  • In the United States District Court for the Eastern District of Michigan
    Case 2:10-cv-10656-AC-MKM Document 1 Filed 02/16/10 Page 1 of 11 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF MICHIGAN ABBOTT LABORATORIES and ) ABBOTT RESPIRATORY LLC, ) ) Plaintiffs, ) ) C.A. No. 2:10-cv-10656 v. ) ) SUN PHARMACEUTICAL INDUSTRIES, LTD. ) and SUN PHARMA GLOBAL FZE, ) ) Defendants. ) COMPLAINT Plaintiffs Abbott Laboratories and Abbott Respiratory LLC (collectively, “Abbott”), by their attorneys, hereby allege as follows: Nature of the Action This is an action for patent infringement of U.S. Patent Nos. 6,080,428 (“the ‘428 patent”) and 6,469,035 (“the ‘035 patent”), arising under the patent laws of the United States, Title 35, United States Code, 35 U.S.C. §§ 271 and 281. This action relates to Abbreviated New Drug Application (“ANDA”) No. 20-0484 filed by Sun Pharma Global FZE (“Sun FZE”) with the U.S. Food and Drug Administration (“FDA”) for approval to market 500 mg and 1000 mg niacin extended-release tablets that are generic versions of the 500 mg and 1000 mg strength versions of Abbott’s highly successful NIASPAN® drug product. Related Actions The present action is related to an identical patent infringement action pending before the United States District Court for the District of Delaware, Abbott Laboratories and Abbott Case 2:10-cv-10656-AC-MKM Document 1 Filed 02/16/10 Page 2 of 11 Respiratory, LLC v. Sun Pharmaceutical Industries, Ltd. and Sun Pharmaceuticals, Inc. (C.A. 10-cv-112) (the “Delaware Sun Action”), pertaining to ANDA No. 20-0484 filed by Sun FZE for approval to market generic versions of Abbott’s 500 mg and 1000 mg strength NIASPAN® tablets.
    [Show full text]
  • Revision in Market Lot of Derivative Contracts on Individual Stocks
    Department : FUTURES & OPTIONS Download Ref No: NSE/FAOP/45895 Date : September 30, 2020 Circular Ref. No: 87/2020 All Members, Revision in Market Lot of Derivative Contracts on Individual Stocks In pursuance of SEBI guidelines for periodic revision of lot sizes for derivatives contracts specified in the SEBI circular CIR/MRD/DP/14/2015 dated July 13, 2015, the market lots of derivatives contracts shall be revised as follows: Sr. Underlying whose Derivative Count of Annexure No Effective date contract size shall be Underlying Number October 30, 2020 (for Nov 1 Revised Downwards 15 1 2020 & later expiries) 2 Revised Upwards 12 October 30, 2020 (for Jan 2 2021 & later expiries) 3 Unchanged 108 - 3 Revised Downwards but new October 30, 2020 (for Jan 4 lot size is not a multiple of old 1 4 2021 & later expiries) lot size To avoid operational complexities, in case of Annexure 2 and 4 above, following will be applicable: 1. Only the far month contract i.e. January 2021 expiry contracts will be revised for market lots. Contracts with maturity of November 2020 and December 2020 would continue to have the existing market lots. All subsequent contracts (i.e. January 2021 expiry and beyond) will have revised market lots. 2. The day spread order book will not be available for the combination contract of Dec 2020 – Jan 2021 expiry. For the purpose of the computation, the average of the closing price of the underlying has been taken for one month period of September 1st – September 30th 2020. This circular shall come into effect from October 30, 2020.
    [Show full text]
  • Cipla Limited
    Cipla Limited Registered Office: Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai – 400 013 Phone: (9122) 2482 6000, Fax: (9122) 2482 6893, Email: [email protected], Website: www.cipla.com Corporate Identity Number: L24239MH1935PLC002380 Annexure to the Board’s Report Particulars of employee remuneration for the financial year ended 31st March, 2019 As required under section 197(12) of the Companies Act, 2013, read with rule 5(2) and (3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014. Employed throughout the year Name Designation Qualification Experience Age Date of Last employment Remuneration (in years) (in years) Employment (Rs.) Abhay Kumar Chief Talent Officer Master of Arts / 17 53 3/10/2016 Piramal Pharma 15,034,298.00 Srivastava Master of Personal Solutions Management Ademola Olukayode Head - Quality Doctorate / MPH / B. 17 48 20/6/2018 US FOOD AND DRUG 17,982,961.00 Daramola Compliance & Tech. ADMINISTRATION Sustainability (US FDA) Ajay Luharuka Head Finance - IPD, B.com,MMS,CFA 23 46 11/7/1996 NIIT Limited 11,922,994.00 API, Specialty & Global Respi Aliakbar Rangwala Senior Business Head M. Sc. / B. Sc. 19 42 19/1/2009 NA 10,677,779.00 - Chronic & Emerging - India Business Alpana Vartak Head - Talent MBA (HR) / B. Sc. 15 41 8/1/2018 Coco - Cola 10,312,782.00 Acquisition Company Anil Kartha Site Head - Bsc, Bpharm 28 56 27/5/1991 Vysali 12,525,338.00 Patalganga - Pharmaceuticals Formulations Anindya Kumar Shee Head - Organization B. Tech. / MBA 18 48 14/1/2016 Reliance Industries 11,084,298.00 Development Ltd.
    [Show full text]
  • DR REDDYS LABORATORIES LTD Form 20-F Filed 2020-06-15
    SECURITIES AND EXCHANGE COMMISSION FORM 20-F Annual and transition report of foreign private issuers pursuant to sections 13 or 15(d) Filing Date: 2020-06-15 | Period of Report: 2020-03-31 SEC Accession No. 0001575872-20-000145 (HTML Version on secdatabase.com) FILER DR REDDYS LABORATORIES LTD Mailing Address Business Address 8-2-337, ROAD NO.3 8-2-337, ROAD NO.3 CIK:1135951| IRS No.: 000000000 | Fiscal Year End: 0331 BANJARA HILLS BANJARA HILLS Type: 20-F | Act: 34 | File No.: 001-15182 | Film No.: 20963158 HYDERABAD K7 500-034 HYDERABAD K7 500-034 SIC: 2834 Pharmaceutical preparations 91 40 49002900 Copyright © 2020 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT ¨ OF 1934 OR þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ¨ 1934 Commission File Number: 1-15182 DR. REDDY’S LABORATORIES LIMITED (Exact name of Registrant as specified in its charter) Not Applicable TELANGANA, INDIA (Translation of Registrant’s name (Jurisdiction of incorporation or into English) organization) 8-2-337, Road No. 3, Banjara Hills Hyderabad, Telangana 500 034, India +91-40-49002900 (Address of principal executive offices) Saumen Chakraborty, Chief Financial Officer, +91-40-49002004, [email protected] 8-2-337, Road No.
    [Show full text]
  • List of Nodal Officer
    List of Nodal Officer Designa S.No tion of Phone (With Company Name EMAIL_ID_COMPANY FIRST_NAME MIDDLE_NAME LAST_NAME Line I Line II CITY PIN Code EMAIL_ID . Nodal STD/ISD) Officer 1 VIPUL LIMITED [email protected] PUNIT BERIWALA DIRT Vipul TechSquare, Golf Course Road, Sector-43, Gurgaon 122009 01244065500 [email protected] 2 ORIENT PAPER AND INDUSTRIES LTD. [email protected] RAM PRASAD DUTTA CSEC BIRLA BUILDING, 9TH FLOOR, 9/1, R. N. MUKHERJEE ROAD KOLKATA 700001 03340823700 [email protected] COAL INDIA LIMITED, Coal Bhawan, AF-III, 3rd Floor CORE-2,Action Area-1A, 3 COAL INDIA LTD GOVT OF INDIA UNDERTAKING [email protected] MAHADEVAN VISWANATHAN CSEC Rajarhat, Kolkata 700156 03323246526 [email protected] PREMISES NO-04-MAR New Town, MULTI COMMODITY EXCHANGE OF INDIA Exchange Square, Suren Road, 4 [email protected] AJAY PURI CSEC Multi Commodity Exchange of India Limited Mumbai 400093 0226718888 [email protected] LIMITED Chakala, Andheri (East), 5 ECOPLAST LIMITED [email protected] Antony Pius Alapat CSEC Ecoplast Ltd.,4 Magan Mahal 215, Sir M.V. Road, Andheri (E) Mumbai 400069 02226833452 [email protected] 6 ECOPLAST LIMITED [email protected] Antony Pius Alapat CSEC Ecoplast Ltd.,4 Magan Mahal 215, Sir M.V. Road, Andheri (E) Mumbai 400069 02226833452 [email protected] 7 NECTAR LIFE SCIENCES LIMITED [email protected] SUKRITI SAINI CSEC NECTAR LIFESCIENCES LIMITED SCO 38-39, SECTOR 9-D CHANDIGARH 160009 01723047759 [email protected] 8 ECOPLAST LIMITED [email protected] Antony Pius Alapat CSEC Ecoplast Ltd.,4 Magan Mahal 215, Sir M.V. Road, Andheri (E) Mumbai 400069 02226833452 [email protected] 9 SMIFS CAPITAL MARKETS LTD.
    [Show full text]
  • Dr. Reddy's Laboratories . Company  Dr
    BY SHIVAM RAJPUT Dr. Reddy's Laboratories . Company Dr. Reddy's Laboratories Ltd, is a pharmaceutical company based in Hyderabad, Andhra Pradesh, India. Headquarters: HYDERABAD, india Founder: Kallam Anji Reddy Founded: 1984 Company Profile The company's first international move took it to Russia in 1992. There, Dr. Reddy's formed a joint venture with the country's biggest pharmaceuticals producer, Biomed. They pulled out in 1995 amid accusations of scandal, involving "a significant material loss due to the activities of Moscow's branch of Reddy's Labs with the help of Biomed's chief executive". Reddy's sold the joint venture to the Kremlin-friendly Sistema group. In 1993, Reddy's entered into a joint venture in the Middle East and created two formulation units there and in Russia. Reddy's exported bulk drugs to these formulation units, which then converted them into finished products. In 1994, Reddy's started targeting the US generic market by building state of art manufacturing facility. In March 2002 Dr Reddy’s acquired BHM Laboratories ,Beverley, and its wholly owned subsidiary meridian health care, EURO 14.81 million. Recently Dr. Reddy’s entered into R & D and Commercialization agreement with Argenta Discovery Ltd, for the treatment of COPD. In march 2006 Dr.reddy’s acquired Betapharm arzneimittel GmbH from 3i for euro 480 million. Betapharm employs more than 350 personnel and its turnover amounts to Euro 186 million . It commands a share of 3.5 % in the German pharmaceutical market. In 2006 – 2007, Dr Reddy’s generated a revenue of EUR 80.5 million from Europe , which accounted for 18% of the company’s total revenue.
    [Show full text]
  • S.No. Scrip Name Symbol Series Leverage (In Times) 1 MARICO
    SCRIPS AVAILABLE FOR INTRADAY WITH LEVERAGES PROVIDED ON THEM Leverage Scrip Name Symbol Series (in times) S.No. 1 MARICO LIMITED MARICO 7.61 2 DABUR INDIA LIMITED DABUR 7.92 3 HINDUSTAN UNILEVER LIMITED HINDUNILVR 7.48 4 COLGATE PALMOLIVE (INDIA) LIMITED COLPAL 7.48 5 NESTLE INDIA LIMITED NESTLEIND 7.39 6 Alkem Laboratories Limited ALKEM 6.91 7 TATA CONSULTANCY SERVICES LIMITED TCS 7.24 8 DR. REDDY'S LABORATORIES LIMITED DRREDDY 6.54 9 PIDILITE INDUSTRIES LIMITED PIDILITIND 7.07 10 GODREJ CONSUMER PRODUCTS LIMITED GODREJCP 5.79 11 POWER GRID CORPORATION OF INDIA LIMITED POWERGRID 6.46 12 ACC LIMITED ACC 6.61 13 NTPC LIMITED NTPC 6.64 14 ITC LIMITED ITC 7.05 15 ASIAN PAINTS LIMITED ASIANPAINT 6.52 16 BRITANNIA INDUSTRIES LIMITED BRITANNIA 6.98 17 BERGER PAINTS (I) LIMITED BERGEPAINT 6.78 18 EXIDE INDUSTRIES LIMITED EXIDEIND 6.89 19 HDFC BANK LIMITED HDFCBANK 6.63 20 DIVI'S LABORATORIES LIMITED DIVISLAB 6.69 21 MRF LIMITED MRF 6.73 22 INDIAN OIL CORPORATION LIMITED IOC 6.49 23 BAJAJ AUTO LIMITED BAJAJ-AUTO 6.64 24 SIEMENS LIMITED SIEMENS 6.40 25 THE RAMCO CEMENTS LIMITED RAMCOCEM 6.23 26 TORRENT POWER LIMITED TORNTPOWER 6.10 27 UNITED BREWERIES LIMITED UBL 6.16 28 INFOSYS LIMITED INFY 6.82 29 CIPLA LIMITED CIPLA 6.52 30 Pfizer Limited PFIZER 6.41 31 PETRONET LNG LIMITED PETRONET 6.45 32 UNITED SPIRITS LIMITED MCDOWELL-N 6.24 33 CADILA HEALTHCARE LIMITED CADILAHC 5.97 34 WIPRO LIMITED WIPRO 6.10 35 SUN PHARMACEUTICAL INDUSTRIES LIMITED SUNPHARMA 6.18 36 BATA INDIA LIMITED BATAINDIA 6.44 37 LARSEN & TOUBRO LIMITED LT 6.38 38 ULTRATECH CEMENT
    [Show full text]
  • LUPIN LIMITED Registered Office: 3Rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai - 400 055
    LUPIN LIMITED Registered Office: 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai - 400 055. Tel:+91 22 6640 2323 Ext: 2402/2403 E-mail: [email protected]; Website: www.lupin.com Corporate Identity Number: L24100MH1983PLC029442 NOTICE OF POSTAL BALLOT Dear Members, Notice pursuant to Section 110 of the Companies Act, 2013 Notice is hereby given pursuant to the provisions of Sections 108 and 110 of the Companies Act, 2013 (Act) read with Rule 22 of the Companies (Management & Administration) Rules, 2014, as amended by the Companies (Management & Administration) Amendment Rules, 2015 and other applicable laws and Regulations that Ordinary Resolutions are proposed to be passed by the Members of the Company through Postal Ballot for the following matters: - 1. To approve the appointment of Mr. K. B. S. Anand (DIN: 03518282), as an Independent Director of the Company, for a period of five years, effective August 12, 2020; 2. To approve the appointment of Dr. Punita Kumar-Sinha (DIN: 05229262), as an Independent Director of the Company, for a period of five years, effective August 12, 2020; 3. To approve the appointment of Mr. Robert Funsten (DIN: 08950420), as an Independent Director of the Company, for a period of six months, effective November 10, 2020; and 4. To approve the appointment of Mr. Mark D. McDade (DIN: 09037255), as an Independent Director of the Company, for a period of five years, effective January 28, 2021. The proposed Resolutions and Explanatory Statements under Section 102(2) of the Act, stating material facts are annexed to this Notice for your consideration.
    [Show full text]